Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; BRINAVESS, a treatment for sinus rhythms in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-ISOTRETINOIN; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include TRULANCE, a once-daily tablet for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation; Trevyent, a drug device combination that delivers treprostinil, the treatment for pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001 for tattoo removal. The company was founded in 2000 and is headquartered in Oakville, Canada.
Read More
